Skip to main content

Advertisement

SpringerLink
Log in

VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the association between the vascular endothelial growth factor (VEGF) gene and response to either intravitreal bevacizumab (IVB) or photodynamic therapy with intravitreal triamcinolone acetonide and IVB (triple therapy) for neovascular age-related macular degeneration (AMD).

Methods

The study consisted of 94 patients with neovascular AMD who underwent IVB and 79 patients with neovascular AMD who underwent triple therapy. Genotypes were determined for four selected tagging single-nucleotide polymorphism (SNP)s of the VEGF gene.

Results

Of the four SNPs studied, one SNP (rs699946) was associated significantly with visual acuity (VA) changes 12 months after treatment—irrespective of whether they received IVB alone (P = 0.044) or triple therapy 0.010). Baseline VA was not significantly different among the three genotypes of rs699946 in either treatment group. There were no significant differences in the number of treatments, incidence of recurrence, or the period until the recurrence according to VEGF rs699946 genetic variant.

Conclusions

The VEGF gene SNP rs699946 was associated with response to IVB alone and to triple therapy in this study. The G allele in SNP rs699946 can thus be applied as a marker for better visual prognosis in patients with neovascular AMD who receive either IVB or triple therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, et al. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006;17:257–66.

    PubMed  Google Scholar 

  2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329–45.

  3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16.

    Article  CAS  PubMed  Google Scholar 

  4. Chakravarthy U, Adamis AP, Cunningham ET, Jr, Goldbaum M, Guyer DR, Katz B, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508 e1–25.

    PubMed  Google Scholar 

  5. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–47.

    Article  PubMed  Google Scholar 

  6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

    Article  CAS  PubMed  Google Scholar 

  7. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–72 e5.

    Article  PubMed  Google Scholar 

  8. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113:633 e1–4.

    Article  PubMed  Google Scholar 

  9. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855–68.

    CAS  PubMed  Google Scholar 

  10. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929–34.

    CAS  PubMed  Google Scholar 

  11. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393–403.

    Article  CAS  PubMed  Google Scholar 

  12. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol. 2009;93:754–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol. 2007;7:10.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65:550–63.

    Article  CAS  PubMed  Google Scholar 

  15. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger EA. Common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37:443–8.

    Article  CAS  PubMed  Google Scholar 

  16. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51:1635–9.

    Article  CAS  PubMed  Google Scholar 

  17. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–5.

    Article  CAS  PubMed  Google Scholar 

  18. Petrovic MG, Korosec P, Kosnik M, Osredkar J, Hawlina M, Peterlin B, et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis. 2008;14:1382–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003;106:468–71.

    Article  CAS  PubMed  Google Scholar 

  20. Diao LP, Yu XM, Gao YH, Li Y, Liu HS, Liu LH, et al. Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin′s lymphoma. J Cancer Res Clin Oncol. 2009;135:1473–81.

    Article  CAS  PubMed  Google Scholar 

  21. Zarbock R, Hendig D, Szliska C, Kleesiek K, Gotting C. Vascular endothelial growth factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum. Hum Mol Genet. 2009;18:3344–51.

    Article  CAS  PubMed  Google Scholar 

  22. Girnita DM, Brooks MM, Webber SA, Burckart GJ, Ferrell R, Zdanowicz G, et al. Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation. 2008;85:1632–9.

    Article  PubMed  Google Scholar 

  23. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res. 2008;14:62–6.

    Article  CAS  PubMed  Google Scholar 

  24. Kim DH, Lee NY, Lee MH, Sohn SK, Do YR, Park JY. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol. 2008;140:71–9.

    Article  CAS  PubMed  Google Scholar 

  25. Immonen I, Seitsonen S, Tommila P, Kangas-Kontio T, Kakko S, Savolainen ER et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology. 2009.

  26. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res. 2005;15:1592–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bewick V, Cheek L, Ball J. Statistics review 10: further nonparametric methods. Crit Care. 2004;8:196–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Goverdhan SV, Hannan S, Newsom RB, Luff AJ, Griffiths H, Lotery AJ. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye. 2008;22:849–54.

    Article  CAS  PubMed  Google Scholar 

  29. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168–73.

    Article  PubMed  Google Scholar 

  30. Brantley MA Jr, Edelstein SL, King JM, Plotzke MR, Apte RS, Kymes SM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye. 2009;23:626–31.

    Article  CAS  PubMed  Google Scholar 

  31. Lee KY, Vithana EN, Mathur R, Yong VH, Yeo IY, Thalamuthu A, et al. Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008;49:2613–9.

    Article  PubMed  Google Scholar 

  32. Gotoh N, Yamada R, Hiratani H, Renault V, Kuroiwa S, Monet M, et al. No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum Genet. 2006;120:139–43.

    Article  CAS  PubMed  Google Scholar 

  33. Fuse N, Miyazawa A, Mengkegale M, Yoshida M, Wakusawa R, Abe T, et al. Polymorphisms in complement factor H and hemicentin-1 genes in a Japanese population with dry-type age-related macular degeneration. Am J Ophthalmol. 2006;142:1074–6.

    Article  CAS  PubMed  Google Scholar 

  34. Uka J, Tamura H, Kobayashi T, Yamane K, Kawakami H, Minamoto A, et al. No association of complement factor H gene polymorphism and age-related macular degeneration in the Japanese population. Retina. 2006;26:985–7.

    Article  PubMed  Google Scholar 

  35. Okamoto H, Umeda S, Obazawa M, Minami M, Noda T, Mizota A, et al. Complement factor H polymorphisms in Japanese population with age-related macular degeneration. Mol Vis. 2006;12:156–8.

    CAS  PubMed  Google Scholar 

  36. Mori K, Gehlbach PL, Kabasawa S, Kawasaki I, Oosaki M, Iizuka H, et al. Coding and noncoding variants in the CFH gene and cigarette smoking influence the risk of age-related macular degeneration in a Japanese population. Invest Ophthalmol Vis Sci. 2007;48:5315–9.

    Article  PubMed  Google Scholar 

  37. Richardson AJ, Islam FM, Guymer RH, Cain M, Baird PN A. Tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. Mol Vis. 2007;13:2148–52.

    PubMed  Google Scholar 

  38. Boekhoorn SS, Isaacs A, Uitterlinden AG, van Duijn CM, Hofman A, de Jong PT, et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology. 2008;115:1899–903.

    Article  PubMed  Google Scholar 

  39. Abhary S, Burdon KP, Gupta A, Lake S, Selva D, Petrovsky N, et al. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:5552–8.

    Article  PubMed  Google Scholar 

  40. Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol. 2009.

  41. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP. VEGF genetic variability is associated with increased risk of developing Alzheimer′s disease. J Neurol Sci. 2009;283:66–8.

    Article  CAS  PubMed  Google Scholar 

  42. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.

    Article  CAS  PubMed  Google Scholar 

  43. Kong SY, Park JW, Lee JA, Park JE, Park KW, Hong EK, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology. 2007;46:446–55.

    Article  CAS  PubMed  Google Scholar 

  44. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48:2422–7.

    Article  CAS  PubMed  Google Scholar 

  45. Pabst S, Karpushova A, Diaz-Lacava A, Herms S, Walier M, Zimmer S et al. VEGF gene haplotypes are associated with sarcoidosis. Chest. 2009.

  46. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond). 2009;23:2223–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Drs Norimoto Gotoh, Hisako Hayashi, Sotaro Ooto, and Hiroshi Tamura for their valuable contributions to this study. This study was supported in part by Grants-in-aid for scientific research (nos. 21249084 and 200791294) from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Japan National Society for the Prevention of Blindness, Tokyo, Japan.

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Kawahara, Shogoin, Sakyo, Kyoto, 606-8507, Japan

    Isao Nakata, Kenji Yamashiro, Hideo Nakanishi, Akitaka Tsujikawa, Atsushi Otani & Nagahisa Yoshimura

  2. Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Isao Nakata & Hideo Nakanishi

Authors
  1. Isao Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Yamashiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideo Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akitaka Tsujikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atsushi Otani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nagahisa Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenji Yamashiro.

About this article

Cite this article

Nakata, I., Yamashiro, K., Nakanishi, H. et al. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol 55, 435–443 (2011). https://doi.org/10.1007/s10384-011-0061-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-011-0061-z

Keywords

Search

Navigation